These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22426151)

  • 21. Arrhythmias and antiarrhythmic drugs.
    Urthaler F
    Ala J Med Sci; 1984 Jul; 21(3):275-83. PubMed ID: 6476289
    [No Abstract]   [Full Text] [Related]  

  • 22. CL-845 (pirmenol hydrochloride): a new orally effective long-acting antiarrhythmic agent.
    Steffe TJ; Mertz TE; Hastings SG; Potoczak RE; Kaplan HR
    J Pharmacol Exp Ther; 1980 Jul; 214(1):50-7. PubMed ID: 7391970
    [No Abstract]   [Full Text] [Related]  

  • 23. [Utilization of anti-arrhythmic drugs].
    Perrenoud JJ
    Schweiz Med Wochenschr; 1980 Jul; 110(29):1090-6. PubMed ID: 6999615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive compounds as antiarrhythmic agents: focus on beta-blocking drugs in ventricular arrhythmias.
    Singh BN; Nademanee K
    Am Heart J; 1987 Oct; 114(4 Pt 2):1040-50. PubMed ID: 2444089
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cardiac side effects of anti-arrhythmia agents].
    Seipel L
    Z Kardiol; 1988 Feb; 77(2):77-88. PubMed ID: 3284219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation.
    Olsson SB; Edvardsson N
    Am Heart J; 1981 Nov; 102(5):864-71. PubMed ID: 7304394
    [No Abstract]   [Full Text] [Related]  

  • 27. Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
    Aupetit JF; Timour Q; Larbre JP; Loufoua-Moundanga J; Kioueh I; Lopez M; Faucon G
    Cardiovasc Drugs Ther; 1993 Apr; 7(2):217-23. PubMed ID: 8357775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination therapy with anti-arrhythmia agents].
    Kettner W; Götze C
    Z Arztl Fortbild (Jena); 1986; 80(21):889-92. PubMed ID: 2436386
    [No Abstract]   [Full Text] [Related]  

  • 29. [The effect of naloxone on rhythm disorders and on the conduction system of the heart].
    Shliakhto EV; Zaĭtsev AA; Panov AV; Ardashev AV; Nifontov EM; Kashina EA; Kazarin VV; Ivanov VV
    Eksp Klin Farmakol; 1996; 59(3):34-6. PubMed ID: 8974581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Supraventricular tachyarrhythmias. Cardiac, extra-cardiac and arrhythmogenic side effects of anti-arrhythmia drugs].
    Meinertz T; Willems S; Weiss C
    Internist (Berl); 1998 Jan; 39(1):33-7. PubMed ID: 9530568
    [No Abstract]   [Full Text] [Related]  

  • 31. [A study of the mechanism of the action of Bunaphtine recording the myocardial monophasic action potentials in man. Conclusive report (author's transl)].
    Bonatti V; Finardi A; Cabasson J; Botti G
    G Ital Cardiol; 1976; 6(8):1378-83. PubMed ID: 1010248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on antiarrhythmic drug pharmacology.
    Huang CL; Wu L; Jeevaratnam K; Lei M
    J Cardiovasc Electrophysiol; 2020 Feb; 31(2):579-592. PubMed ID: 31930579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-arrhythmic drugs and heart conduction].
    Furlanello F
    G Clin Med; 1973 Jul; 54(7):382-406. PubMed ID: 4779853
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of ventricular arrhythmias.
    Fogoros RN
    Am Fam Physician; 1986 Mar; 33(3):236-46. PubMed ID: 3953344
    [No Abstract]   [Full Text] [Related]  

  • 35. Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans.
    Kjølbye AL; Dikshteyn M; Eloff BC; Deschênes I; Rosenbaum DS
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H41-9. PubMed ID: 17982010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac arrhythmogenesis: a tale of two clocks?
    Lei M; Huang CL
    Cardiovasc Res; 2020 Dec; 116(14):e205-e209. PubMed ID: 31800017
    [No Abstract]   [Full Text] [Related]  

  • 37. Electrophysiologic and pharmacokinetic profile of the new antiarrhythmic drug TYB-3823 in humans.
    Crijns HJ; Oosterhuis B; Wiesfeld AC; De Bruin H; Mensink CK; Jonkman JH; Kozma C; Lie KI
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):1-6. PubMed ID: 7678662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of cardiac arrhythmias--basic science for clinicians.
    Shu J; Zhou J; Patel C; Yan GX
    Pacing Clin Electrophysiol; 2009 Nov; 32(11):1454-65. PubMed ID: 19744278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation.
    Kirchhof P; Degen H; Franz MR; Eckardt L; Fabritz L; Milberg P; Läer S; Neumann J; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2003 Apr; 305(1):257-63. PubMed ID: 12649377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Action of various anti-arrhythmia agents on atrioventricular conduction studied by recording of His bundle potentials in humans. Preliminary study].
    Moulin MA; Potier JC; Bernard JP; Foucault JP
    Therapie; 1973; 28(1):43-54. PubMed ID: 4731483
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.